Prescribing information

 

Prescribing information

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Resources for HCPs to share with patients who have been prescribed ILARIS® (canakinumab) to treat their periodic fever syndrome.

This video will help patients and caregivers learn the correct injection technique when administering ILARIS*.

Do not share links to this website or screenshots with patients as this website is intended for healthcare professionals only. If you do wish to share this video with patients, please share this link: https://health.novartis.co.uk/public/medicines/rare-diseases/ilaris/patient-resources/administration-video

 

 

*Treatment should be initiated and supervised by a specialist physician. After proper training, if the physician determines that it is appropriate, patients or their caregivers may inject Ilaris.

Patient guide to ILARIS® treatment

document guide for English version of a booklet about what ILARIS is, how it works, and things to know before starting treatment.

English version of a booklet about what ILARIS is, how it works, and things to know before starting treatment.

Download

document guide for Arabic version of a booklet about what ILARIS is, how it works, and things to know before starting treatment.

Arabic version of a booklet about what ILARIS is, how it works, and things to know before starting treatment.

Download

document guide for Turkish version of a booklet about what ILARIS is, how it works, and things to know before starting treatment.

Turkish version of a booklet about what ILARIS is, how it works, and things to know before starting treatment.

Download

Guides to periodic fever syndromes

document guide to periodic fever syndromes for adult patients, including what causes them and how ILARIS can help.

A guide to periodic fever syndromes for adult patients, including what causes them and how ILARIS can help.

Download

document guide to periodic fever syndromes for paediatric patients, including what causes them and how ILARIS can help.

A guide to periodic fever syndromes for paediatric patients, including what causes them and how ILARIS can help.

Download

 

Guides to Still’s disease

document guide to Still’s disease for adult patients, including what causes them and how ILARIS can help

A guide to Still’s disease for adult patients, including what causes them and how ILARIS can help.

Download

document guide to Still’s disease for paediatric patients, including what causes them and how ILARIS can help.

A guide to Still’s disease for paediatric patients, including what causes them and how ILARIS can help.

Download

Indications
Periodic fever syndromes
ILARIS is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:1

  • CAPS, including:
    • Muckle-Wells syndrome (MWS)
    • Neonatal-onset multisystem inflammatory disease (NOMID)/chronic infantile neurological, cutaneous, articular syndrome (CINCA)
    • Severe forms of familial cold autoinflammatory syndrome (FCAS)/familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash
  • TRAPS
  • HIDS/MKD
  • FMF
    • ILARIS should be given in combination with colchicine, if appropriate.

Still’s disease
ILARIS is indicated for the treatment of active Still's disease including adult-onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. ILARIS can be given as monotherapy or in combination with methotrexate.1

CAPS, cryopyrin-associated periodic syndromes; FMF, familial Mediterranean fever; HCP, healthcare professional; HIDS, hyperimmunoglobulin D syndrome; MKD, mevalonate kinase deficiency; TRAPS, tumour necrosis factor receptor-associated periodic syndrome.

Reference:

  1. ILARIS® (canakinumab) Summary of Product Characteristics.

 

Rate this content: 
Average: 5 (1 vote)
UK | April 2022 | 200186
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]